PBU The Pension Fund of Early Childhood & Youth Educators Takes $7.08 Million Position in Amgen Inc. $AMGN

PBU The Pension Fund of Early Childhood & Youth Educators acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, Holdings Channel reports. The fund acquired 21,624 shares of the medical research company’s stock, valued at approximately $7,078,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lifestyle Asset Management Inc. raised its stake in shares of Amgen by 6.5% in the 4th quarter. Lifestyle Asset Management Inc. now owns 863 shares of the medical research company’s stock worth $282,000 after buying an additional 53 shares in the last quarter. Prestige Wealth Management Group LLC raised its stake in shares of Amgen by 120.8% in the 4th quarter. Prestige Wealth Management Group LLC now owns 3,213 shares of the medical research company’s stock worth $1,052,000 after buying an additional 1,758 shares in the last quarter. SlateStone Wealth LLC raised its stake in shares of Amgen by 1.3% in the 4th quarter. SlateStone Wealth LLC now owns 36,308 shares of the medical research company’s stock worth $11,884,000 after buying an additional 476 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. raised its stake in shares of Amgen by 8.3% in the 4th quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. now owns 5,959 shares of the medical research company’s stock worth $1,950,000 after buying an additional 459 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd raised its stake in shares of Amgen by 28.3% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 48,412 shares of the medical research company’s stock worth $15,845,000 after buying an additional 10,678 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by company insiders.

Amgen Stock Up 1.2%

Shares of Amgen stock opened at $349.58 on Friday. The stock’s fifty day moving average is $341.35 and its 200-day moving average is $345.47. The firm has a market capitalization of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.51 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Jefferies Financial Group assumed coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective on the stock. Finally, UBS Group boosted their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $353.81.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.